Enanta Pharmaceuticals (FRA:9EP) 3-Year Book Growth Rate : -32.50% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Enanta Pharmaceuticals 3-Year Book Growth Rate?

Enanta Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2024 was €5.01.

During the past 12 months, Enanta Pharmaceuticals's average Book Value per Share Growth Rate was -42.20% per year. During the past 3 years, the average Book Value per Share Growth Rate was -32.50% per year. During the past 5 years, the average Book Value per Share Growth Rate was -23.50% per year. During the past 10 years, the average Book Value per Share Growth Rate was -1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Enanta Pharmaceuticals was 32.00% per year. The lowest was -32.50% per year. And the median was 12.90% per year.

Competitive Comparison of Enanta Pharmaceuticals's 3-Year Book Growth Rate

For the Biotechnology subindustry, Enanta Pharmaceuticals's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enanta Pharmaceuticals's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's 3-Year Book Growth Rate falls into.

Save Embed

;

Save Embed

;

Enanta Pharmaceuticals 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Enanta Pharmaceuticals (FRA:9EP) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Enanta Pharmaceuticals 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Enanta Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enanta Pharmaceuticals Inc (FRA:9EP) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

ENTA:USA

Address

4 Kingsbury Avenue, Watertown, MA, USA, 02472

Website

https://www.enanta.com

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Enanta Pharmaceuticals Headlines

No Headlines